NIH partners 11 drugmakers to accelerate cancer therapy research


Oct 12 (Reuters) - The National Institutes of Health said on Thursday it had partnered 11 biopharma companies to help advance a new class of drugs that uses the body's immune system to fight cancer.

The five-year public-private research collaboration, called Partnership for Accelerating Cancer Therapies, includes drugmakers AbbVie, Roche Holding AG and Bristol-Myers Squibb.

The new class of immunotherapies, such as Roche's Tecentriq and Bristol-Myers' Opdivo, works by enlisting the body's defenses to fight the tumours.

Pfizer Inc, Johnson & Johnson, Amgen Inc, Celgene Corp, Gilead Sciences Inc and GlaxoSmithKline Plc are part of the effort, NIH said.

The 11 partners would contribute up to $1 million each year for five years, while NIH would add about $160 million, based on availability of funds.

The partnership will be managed by the Foundation for the National Institutes of Health.

This article appears in: Stocks , World Markets , Economy
Referenced Symbols: ABBV ,

More from Reuters


See headlines for ABBV

Research Brokers before you trade

Want to trade FX?